Design Therapeutics Inc (DSGN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Design Therapeutics Inc (DSGN) has a cash flow conversion efficiency ratio of -0.056x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-11.16 Million) by net assets ($199.72 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Check Design Therapeutics Inc PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Design Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Design Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. See Design Therapeutics Inc (DSGN) net assets for net asset value and shareholders' equity analysis.
Design Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Design Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Better Home & Finance Holding Company
NYSE:BETR
|
-0.797x |
|
Pondy Oxides & Chemicals Limited
NSE:POCL
|
0.171x |
|
Fujian Oriental Silver Star Investment Co Ltd
SHG:600753
|
-0.569x |
|
Nanjing TDH Technology Co. Ltd. A
SHE:301378
|
N/A |
|
Shanxi C&Y Pharmaceutical Group Co Ltd
SHE:300254
|
0.092x |
|
Lionco Pharm Grp Co Ltd
SHG:603669
|
-0.127x |
|
Guoanda Co Ltd
SHE:300902
|
0.001x |
|
Renxin New Material Co. Ltd. A
SHE:301395
|
N/A |
Annual Cash Flow Conversion Efficiency for Design Therapeutics Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Design Therapeutics Inc from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see DSGN company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $242.10 Million | $-43.10 Million | -0.178x | +15.57% |
| 2023-12-31 | $277.69 Million | $-58.56 Million | -0.211x | -34.51% |
| 2022-12-31 | $327.31 Million | $-51.32 Million | -0.157x | -103.94% |
| 2021-12-31 | $382.13 Million | $-29.38 Million | -0.077x | -110.03% |
| 2020-12-31 | $-11.31 Million | $-8.67 Million | 0.766x | +1907.43% |
| 2019-12-31 | $-3.64 Million | $-139.00K | 0.038x | -- |
About Design Therapeutics Inc
Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potenti… Read more